These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32448372)

  • 21. Sex as a Critical Variable in Basic and Pre-Clinical Studies of Fibrodysplasia Ossificans Progressiva.
    Burdick LN; DelVichio AH; Hanson LR; Griffith BB; Bouchard KR; Hunter JW; Goldhamer DJ
    Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice.
    Yamamoto R; Matsushita M; Kitoh H; Masuda A; Ito M; Katagiri T; Kawai T; Ishiguro N; Ohno K
    J Bone Miner Metab; 2013 Jan; 31(1):26-33. PubMed ID: 23011467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent.
    Upadhyay J; Xie L; Huang L; Das N; Stewart RC; Lyon MC; Palmer K; Rajamani S; Graul C; Lobo M; Wellman TJ; Soares EJ; Silva MD; Hesterman J; Wang L; Wen X; Qian X; Nannuru K; Idone V; Murphy AJ; Economides AN; Hatsell SJ
    J Bone Miner Res; 2017 Dec; 32(12):2489-2499. PubMed ID: 28782882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
    Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN
    Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell Senescence in Heterotopic Ossification.
    Pignolo RJ; Kaplan FS; Wang H
    Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
    Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
    Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rarely occurring mutation of ACVR1 gene in Moroccan patient with fibrodysplasia ossificans progressiva.
    Ratbi I; Bocciardi R; Regragui A; Ravazzolo R; Sefiani A
    Clin Rheumatol; 2010 Jan; 29(1):119-21. PubMed ID: 19795179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hints on transcriptional control of essential players in heterotopic ossification of Fibrodysplasia Ossificans Progressiva.
    Ravazzolo R; Cappato S; Bocciardi R
    Bone; 2018 Apr; 109():187-191. PubMed ID: 29100956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva.
    Srinivasan D; Arostegui M; Goebel EJ; Hart KN; Aykul S; Lees-Shepard JB; Idone V; Hatsell SJ; Economides AN
    Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva.
    Shore EM; Kaplan FS
    Curr Osteoporos Rep; 2011 Jun; 9(2):83-8. PubMed ID: 21340697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrodysplasia ossificans progressiva: clinical and genetic aspects.
    Pignolo RJ; Shore EM; Kaplan FS
    Orphanet J Rare Dis; 2011 Dec; 6():80. PubMed ID: 22133093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():497-502. PubMed ID: 30171563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptomic Differences Underlying the Activin-A Induced Large Osteoclast Formation in Both Healthy Control and Fibrodysplasia Ossificans Progressiva Osteoclasts.
    Schoenmaker T; Zwaak J; Loos BG; Volckmann R; Koster J; Eekhoff EMW; de Vries TJ
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Fibrodysplasia ossificans progressiva and osteoimmunology].
    Katagiri T
    Clin Calcium; 2016 May; 26(5):691-8. PubMed ID: 27117614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva.
    Towler OW; Shore EM; Kaplan FS
    Bone; 2020 Jan; 130():115116. PubMed ID: 31655222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrodysplasia ossificans progressiva.
    Kaplan FS; Le Merrer M; Glaser DL; Pignolo RJ; Goldsby RE; Kitterman JA; Groppe J; Shore EM
    Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):191-205. PubMed ID: 18328989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
    Kaplan FS; Xu M; Seemann P; Connor JM; Glaser DL; Carroll L; Delai P; Fastnacht-Urban E; Forman SJ; Gillessen-Kaesbach G; Hoover-Fong J; Köster B; Pauli RM; Reardon W; Zaidi SA; Zasloff M; Morhart R; Mundlos S; Groppe J; Shore EM
    Hum Mutat; 2009 Mar; 30(3):379-90. PubMed ID: 19085907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibrodysplasia ossificans progressiva-related activated activin-like kinase signaling enhances osteoclast formation during heterotopic ossification in muscle tissues.
    Yano M; Kawao N; Okumoto K; Tamura Y; Okada K; Kaji H
    J Biol Chem; 2014 Jun; 289(24):16966-77. PubMed ID: 24798338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene Therapy for Fibrodysplasia Ossificans Progressiva: Feasibility and Obstacles.
    Eekhoff EMW; de Ruiter RD; Smilde BJ; Schoenmaker T; de Vries TJ; Netelenbos C; Hsiao EC; Scott C; Haga N; Grunwald Z; De Cunto CL; di Rocco M; Delai PLR; Diecidue RJ; Madhuri V; Cho TJ; Morhart R; Friedman CS; Zasloff M; Pals G; Shim JH; Gao G; Kaplan F; Pignolo RJ; Micha D
    Hum Gene Ther; 2022 Aug; 33(15-16):782-788. PubMed ID: 35502479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.
    Wentworth KL; Masharani U; Hsiao EC
    Br J Clin Pharmacol; 2019 Jun; 85(6):1180-1187. PubMed ID: 30501012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.